Molecular Partners Ag (MOLN) Treasury Shares (2022 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Treasury Shares of -$1446.8 for Q1 2026, down 32.6% year-on-year from -$2146.7 in Q1 2025, and down 2.43% on a QoQ basis from -$1412.6 in Q4 2025.
Molecular Partners Ag (MOLN) Treasury Shares (2022 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Treasury Shares for 5 consecutive years, with -$1446.8 the latest figure, recorded in Q1 2026.
- Quarterly Treasury Shares fell 32.6% year-over-year to -$1446.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1446.8 (down 32.6% YoY) and the FY2025 annual result came in at -$1412.6, down 100.13% from the prior year.
- Treasury Shares retreated to -$1446.8 in Q1 2026 per MOLN's latest filing, from -$1412.6 in the prior quarter.
- Over the last five years, Treasury Shares for MOLN reached as high as $1.1 million in Q4 2024 and fell as low as -$1.1 million in Q2 2023.
- A 5-year average of $70405.1 and a median of -$1123.9 in 2024 frame the typical range for Treasury Shares.
- The largest YoY upside for Treasury Shares was 99.87% in 2025 against a maximum downside of 100.13% in 2025.
- Year by year, Treasury Shares stood at $1.0 million in 2022, then rose by 8.61% to $1.1 million in 2023, then climbed by 1.26% to $1.1 million in 2024, then sank by 100.13% to -$1412.6 in 2025, then retreated by 2.43% to -$1446.8 in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered -$1446.8, -$1412.6, and -$1411.4 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 265,401.92 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 19.41 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 5.14 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -1,446.85 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,446.85 |
| Mar 31, 2026 | -1,446.85 |
| Dec 31, 2025 | -1,412.57 |
| Dec 31, 2025 | -1,412.57 |
| Sep 30, 2025 | -1,411.37 |
| Sep 30, 2025 | -1,411.37 |
| Jun 30, 2025 | -1,361.29 |
| Jun 30, 2025 | -1,361.29 |
| Mar 31, 2025 | -1,091.12 |
| Mar 31, 2025 | -1,091.12 |
| Dec 31, 2024 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | -1,132.28 |
| Sep 30, 2024 | -1,132.28 |
| Jun 30, 2024 | -1.08 Mn |
| Jun 30, 2024 | -1.08 Mn |
| Mar 31, 2024 | -1,123.91 |
| Mar 31, 2024 | -1,123.91 |
| Dec 31, 2023 | 1.11 Mn |
| Dec 31, 2023 | 1.11 Mn |